 BETHLEHEM, Pa., Jan. 21, 2021 GLOBE NEWSWIRE -- OraSure Technologies, Inc. NASDAQ: OSUR, a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OrageneDx OGD-610 saliva collection device was included as a component in the De Novo authorization granted by the U.S. Food Drug Administration FDA to Helix for their Helix Laboratory Platform1, a whole exome sequencing platform. This is the first exome sequencing-based platform authorized by the FDA. OrageneDx is a product of OraSures DNA Genotek subsidiary. 